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Abstract
Background: Cancer metastasis is determined by the formation of the metastatic niche and the ability of cancer
cells to adapt to microenvironmental stresses. Anoikis resistance is a fundamental feature of metastatic cancer cell
survival during metastatic cancer progression. However, the mechanisms underlying anoikis resistance in ovarian
cancer are still unclear.
Methods: Expressions of miRNA-141 and its downstream targets were evaluated by qPCR, Western blotting,
Immunohistochemical (IHC) and in situ hybridization (ISH) assays. The luciferase assays were used to prove KLF12 as
the downstream target of miR-141. The cDNA microarray and apoptotic protein arrays were used to identify the
targets of miR-141 and KLF12. The competition of KLF12 and Sp1 on survivin promoter was examined by ChIP
assay. IHC analysis on ovarian cancer tissue array was used to evaluate the expressions of KLF12 and miR-141 and
to show the clinical relevance. The functional studies were performed by in vitro and in vivo tumorigenic assays.
Results: Enforced expression of miR-141 promotes, while knockdown of miR-141 expression inhibits, cell proliferation,
anchorage-independent capacity, anoikis resistance, tumor growth and peritoneal metastases of ovarian cancer cells.
Bioinformatics and functional analysis identified that Kruppel-related zinc finger protein AP-2rep (KLF12) is directly
targeted by miR-141. Consistent with this finding, knockdown of KLF12 phenocopied the effects of miR-141
overexpression in ovarian cancer cells. In contrast, restoration of KLF12 in miR-141-expressing cells significantly
attenuated anoikis resistance in ovarian cancer cells via interfering with Sp1-mediated survivin transcription, which
inhibits the intrinsic apoptotic pathway and is crucial for ovarian cancer cell survival, anoikis resistance and peritoneal
metastases. Immunohistochemical (IHC) and in situ hybridization (ISH) assays confirmed that miRNA-141 expression is
inversely correlated with KLF12 expression and significantly associated with advanced ovarian cancers accompanied
with distal metastases, underscoring the clinical relevance of our findings.
Conclusions: Our data identify a novel signaling axis of miR-141/KLF12/Sp1/survivin in enhancing anoikis resistance
and likely serves as a potential therapeutic target for metastatic ovarian cancer.
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Background
Epithelial ovarian cancer (EOC) is the most lethal
gynecological malignancy worldwide. This disease is
generally called the “silent killer” because there are no
symptoms, and thus, the majority of patients are diag-
nosed when the cancer is at an advanced stage with
extensive micrometastases [1]. Most deaths from this
cancer are attributed to metastatic progression [1].
Therefore, understanding the molecular mechanisms of
metastases may assist in the development of targeted
therapies to improve the outcomes of this disease.
Cancer metastasis is determined by the formation of the
metastatic niche and the ability of cancer cells to adapt
to the microenvironment [2]. However, the associated
molecular mechanisms remain unclear.
Metastasis is a multistep process that allows cancer
cells to spread from the primary site to a distant location
in the body and includes local invasion, intravasation,
circulation, extravasation, proliferation and angiogenesis
[3]. Among the steps that occur during cancer cell me-
tastasis, escaping apoptosis (i.e., anoikis resistance) while
detaching from the extracellular matrix or neighboring
cells at the primary sites and circulating in transit to a
distant location is of utmost importance. Many studies
have suggested that the upregulation of oncogenes or
the loss of tumor suppressors in the signaling pathways
associated with the death receptor (extrinsic), mitochon-
drial (intrinsic) and convergence pathways (IAPs) allows
tumor cells to circumvent anoikis to evade restriction by
integrin–ECM interactions [4]. Unlike other cancers,
peritoneal metastases is the most common route of
ovarian cancer metastasis [5]. But similar to other can-
cers, micrometastases is the commonly cause of ovarian
cancer recurrence as well as chemoresistance [6]. The
detached ovarian cancer cells acquire anoikis resistance
to survive in the ascitic fluid prior to metastatic
colonization in the omentum/peritoneum is a vital trait
of metastatic progression [7, 8].
Emerging evidence has indicated that deregulation of
miRNAs is involved in cancer metastases [9]. Micro-
RNAs (miRNA) are small endogenous, non-coding
RNAs of 21 to 25 nucleotides [10, 11] that negatively
regulate gene expression by translational repression or
endonucleolytic cleavage of the target mRNAs [12, 13]
at the post-transcriptional level. Since 2002, emerging
evidence has suggested that the aberrant expression of
miRNAs in human cancers may modulate tumor pro-
gression by regulating tumor suppressors and oncogenes
[14]. For example, miR-221/222 has been shown to in-
crease chemoresistance in breast cancer [15], increase
tumorigenicity of cancer cells through PTEN [16], pro-
mote human castration-resistant prostate cancer devel-
opment [17] and stimulate invasion in glioblastoma [18].
Another example is the miR-200 family, which facilitates
endometrioid carcinoma growth by modulating the
Notch, p53, MAPK, and ErbB signaling pathways [19, 20].
However, the functional roles of miRNAs associated with
anoikis resistance in human ovarian cancer have rarely
been investigated.
In this study, we found that a member of the miR-200
family, miR-141, is prominently overexpressed in ad-
vanced and metastatic ovarian cancers. Using a series of
functional and biochemical analyses, we identified that
miR-141 enhances resistance against microenvironmen-
tal stresses and anoikis by targeting and repressing
KLF12 expression, which allows Sp1 to upregulate
survivin expression, an inhibitor of intrinsic apoptotic
pathway, is crucial in promoting cell survival, prolifera-
tion and peritoneal metastases of ovarian cancer.
Methods
Cell culture and human tissue samples
The human ovarian cancer cell lines; SKOV3 (purchased
from American Type Culture Collection, ATCC),
OVCA433 and A2780cp and cervical cancer cell lines
(OV2008 and C13*) (kindly provided by Prof. B. Tsang,
Department of Obstetrics and Gynecology, University of
Ottawa) were used in this study. They were grown either
in Dulbecco’s modified Eagle’s medium (DMEM) or in
minimum essential medium (MEM) (Invitrogen, Grand
Island, N.Y., USA) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen) and 1% penicillin-streptomycin
(P/S) (Invitrogen). Three human immortalized ovarian
surface epithelial cell lines, HOSE 17–1, HOSE 11–12
and HOSE 96-9-10 (kindly provided by Prof. GSW. Tsao,
The University of Hong Kong) [21], were cultured in
Medium 199 and Medium 105 (Sigma-Aldrich Corp., St.
Louis, MO, USA) supplemented with 10% FBS and 1%
P/S. All cells were incubated in an incubator containing
5% CO2 at 37 °C. In-house STR DNA profiling analysis
was used to authenticate the cell lines, and mycoplasma
contamination was assessed. All clinical samples (49
ovarian cancer tissues and 12 normal ovarian tissues) were
obtained from the Department of Obstetrics and
Gynecology of The University of Hong Kong at Queen
Mary Hospital. The specimens were snap-frozen immedi-
ately after collection and were stored at −80 °C until use.
Plasmids and cell transfection
The miR-141-expressing construct (pmR-ZsGreen1-
miR-141) (Forward -TTGAGCTGAAAGCTTTGCACA
AGG, Reverse-AAGTGACTTGGATCCG, 583 bp) was
generated by PCR amplification and ligated into the
pmR-ZsGreen1 plasmid (Clontech, Mountain View,
CA). The KLF12-expressing construct (pCMV6-KLF12)
and Sp1-expressing construct (pCMV6-Sp1) were pur-
chased from Origene (Origene Technologies, Inc.,
Rockville, M.D., USA). The Ambion® Anti-miR™ miRNA
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Inhibitor targeting miR-141 was purchased from
ThermoFisher (ThermoFisher Scientific, Waltham, MA,
USA). A TriFECTa® Kit with 3 siRNAs (KD1:
NM_007249 duplex 1, KD2: NM_007249 duplex 2, KD3:
NM_007249 duplex 3) and shRNA (NM_007249.4) tar-
geting KLF12 were purchased from Integrated DNA
Technologies (IDT, Commercial Park, Coralville, IA,
USA) and GeneCopoeia (GeneCopoeia, Inc., USA). The
universal negative control RNA duplex (NC1), scram-
bled siRNA control and shRNA scrambled control clone
for psi-HIV-U6 were used as the negative controls. For
luciferase reporter assays, pairs of oligonucleotides con-
taining the 3'UTR binding site for miR-141 were pur-
chased from IDT. Cell transfection was performed using
Lipofectamine™ 2000 (Invitrogen) according to the man-
ufacturer’s instructions. Stable clones overexpressing
miR-141 were harvested after approximately 2 weeks of
G418 selection. The transiently silenced KLF12 cells
were collected at 48 h post-transfection, and lentivirus
was used to infect cancer cells with KLF12 shRNA.
RNA extraction and quantitative real-time PCR
TRIzol reagent (Invitrogen, Life Technologies) was used
to extract total RNA from cell lines and primary cancer
tissue samples. Twenty-five nanograms of total RNA was
used as a template to generate first-strand cDNA with
miRCURY LNA™ Universal RT microRNA PCR using a
Universal cDNA Synthesis Kit (Exiqon, Vedbaek,
Denmark). Quantitative real-time PCR (QPCR) was per-
formed using a miRCURY LNA™ Universal RT miRNA
PCR Kit and SYBR Green master mix (Exiqon, Denmark)
in an ABI 7500 system (Applied Biosystems). The miR-
141 probes (product no. 204504) and SNORD48, the ref-
erence gene (product no. 203903), were purchased from
Exiqon. Each sample was assayed in triplicate, and the
relative expression of miR-141 was normalized to
SNORD48.
Cell viability assays, cell migration and anoikis assays
Cell viability was measured by XTT assays, foci forma-
tion assays and soft agar assays. For the XTT assay, ap-
proximately 1000–2000 cells were seeded into each well
of a 96-well plate. The full serum medium was changed
to 1% serum medium after cell seeding for 24 h. Cell via-
bility was measured using a Cell Proliferation Kit II
(Roche Biosciences, Indianapolis, IN, USA) according to
the manufacturer’s instructions. To perform the foci for-
mation assay, cells were seeded in 6-well plates at a
density of 800 cells/well. After seeding the cells for 24 h,
the medium was exchanged with 1% serum medium.
After approximately 1–2 weeks, the colonies that formed
were fixed with 70% ethanol for 30 min before staining
with 20% Giemsa stain (Sigma). The foci were counted.
The soft agar assay was used to examine the anchorage-
independent growth of ovarian cancer cells. Cancer cells
with a density ranging from 500 to 1000 cells/well were
embedded in a 0.6% DMEM-agarose layer on top of a
2% DMEM-agarose base. After 14 to 21 days, the viable
colonies with >20 cells were counted. The cell migratory
capacity of ovarian cancer cells was examined by the
Transwell cell migration assay kits (Chemicon Inter-
national, Inc., Temecula, CA) according to the manufac-
turer’s instructions. The migratory cells on transwell
filters were visualized counted by bright-field micros-
copy (TE300, Nikon). For the anoikis assay, 1 × 106 cells
were cultured in the wells of 6-well low-attachment
plates pre-coated with 1% agarose gel. After 48 h of sus-
pension, cells were harvested for cell death analysis by
TUNEL assays and flow cytometry. Cleavage of PARP and
cleavage of caspase3 were evaluated by western blotting.
The results were generated from more than three separate
experiments and are presented as the mean ± SD.
Computational miRNA target prediction and RNA gene
expression profiling
Three online programs, TargetScan 6.0 (http://www.targets-
can.org/), PicTar (http://pictar.mdc-berlin.de/) and
DIANA LAB (DIANA-microT web server v5.0, http://
diana.imis.athena-innovation.gr/DianaTools/index.php?r=
MicroT_CDS/index), were used to identify potential
targets of miR-141. For the gene expression profiling, total
RNA was extracted from KLF12 knockdown OVCA433
cells and the vector control cells. OD260/280 ratios (1.7-2.1)
and RNA integrity number (RIN > 0.8) of the RNA
samples were analyzed by a spectrophotometer and
bioanalyzer, respectively. After verifying the quality, the
samples were subjected to Affymetrix GeneChip processing
(Human Genome U133 Plus 2.0 Array) in the Centre for
Genomic Science, The University of Hong Kong. The
GeneChip experiment labels RNA targets and hybridizes
targets to the arrays, followed by stringent washes, staining
and scanning. The data were analyzed by GeneSpring 12.6
(Agilent Technologies, Santa Clara, USA).
Sp1 binding site prediction, Chromatin
immunoprecipitation (ChIP) and Luciferase reporter
assays
Sp1 motif (MA0079.3) in JASPAR CORE Vertebrata data-
base is represented in terms of the Position Weight Matrix
(PWM), as annotated in the TRANSFAC® database. It was
used to scan Sp1 binding sites (BS) in BIRC5 pro-
moter, +/−1 k to TSS, chr17:76209278–76211277
(based on hg19 genome assembly), and ten putative BS
were found. Five of them are covered by Sp1 ChIP-Seq
peaks in 2 studies from ENCODE (Sp1 ChIP-Seq in A549
and HCT116), and two of the five are even covered by
Sp1 ChIP-Seq peaks in 3 more studies from ENCODE
(Sp1 ChIP-Seq in GM12878, H1-hESC and HepG2).
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The Chromatin immunoprecipitation (ChIP) Assay Kit
(Millipore, Billerica, MA, USA) was used to investigate
the competition binding of Sp1 and KLF12 on human sur-
vivin promoter. The immunoprecipitated chromatin was
examined by PCR and the ChIP primers targeted the sur-
vivin promoter is shown (Additional file 1: Figure S3).
Luciferase constructs were generated by ligating oligonu-
cleotides containing wild-type (KLF12, sense: 5'-CTC
CCCTTCACAGTGTTAACACAAAAGGGC ATCACCA
TCCCACGATGTCTGT-3'; antisense: 5'-CTAGACAGAC
ATCGTG GGATGGTGATGCCCTTTTGTGTTAACAC
TGTGAAGGGGAGAGCT-'’; E2F3, sense: 5'-CATGGA
ACCAGAACATCTGTCATGCAGTGTTGTCCCTT CCT
ACCTTCTTCCT-3'; antisense: 5'-CTAGAGGAAGAAGG
TAGGAAGGG ACAACACTGCATGACAGATGTTCTG
GTTCCATGAGCT-3'; MAP2K4 sense: 5'-CGT AATA
CCTGATTGATCACACAGTGTTAGTGCTGGTCAGAG
AGACCTCATT-3'; antisense: 5'-CTAGAATGAGGTCT
CTCTGACCAGCACT AACACTGTGTGATCAATCAG
GTATTACGAGCT-3') or mutant (KLF12, sense: 5'-CT
CCCCTTCACAGAGAAAACACAAAAGGGCATCACC
ATCCCA CGATGTCTGT-3'; antisense: 5'-CTAGACA
GACATCGTGGGATGGTGATGC CCTTTTGTGTTTT
CTCTGTGAAGGGGAGAGCT-3') 3'UTR binding sites
of miR-141 into the multi-cloning region of the pmirGLO
Dual-Luciferase miRNA Target Expression Vector
(Promega, Madison, WI, USA). HEK-293 cells were
seeded into a 24-well plate and co-transfected with 100 ng
pmirGLO wild-type or mutant plasmids together with the
pmR-141 plasmid and the pmR-ZsGreen1 empty vector as
a control (400 ng in total) using Lipofectamine™ 2000
(Invitrogen). Luciferase activity was detected with a Dual-
luciferase Assay Kit (Promega) 48 h post-transfection using
a F-4500 fluorescence spectrophotometer (Promega). For
the dose-dependent model, 200, 400 and 600 ng of
pmR-141 and constant amounts of the KLF12 plasmid
(200 ng) were co-transfected into HEK-293 cells.
Renilla luciferase activity was used as the reference to
normalize transfection efficiency. All experiments were
repeated three times.
Western blotting and human apoptosis array
Cells were harvested and lysed using lysis buffer (Cell
Signaling Technology) containing protease inhibitors
(Sigma) and phenylmethylsulfonyl fluoride (PMSF)
(Sigma Chemical Co., St Louis, MO, USA). Equal
amounts of protein were separated by 10% SDS-PAGE
and then transferred to Immobilon-P Transfer Mem-
branes (Millipore Corporation, Bedford, MA, USA). The
membranes were pre-blotted in 5% skim milk prior to
incubation in 1% skim milk containing primary anti-Sp1
(1:500; Millipore Darmstadt, Germany), anti-KLF12 and
anti-XIAP (1:1000; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), anti-cleaved-PARP, anti-cleaved-caspase3
(1:1000; Cell Signaling Technology, Inc., Danvers), anti-
DDK (1:1000) (OriGene Technologies, Rockville, MD)
and anti-β-actin (1:10000; Sigma-Aldrich, St. Louis, MO)
antibodies overnight. The membranes were incubated
with horseradish peroxidase-conjugated goat anti-rabbit
or anti-mouse IgG (Amersham) and visualized using
ECLTM Western Blotting Detection Reagent (Amersham).
Images were captured by Fuji Medical X-Ray Film (Fuji)
and developed by the Fuji system. The Human Apoptosis
Array Kit (R&D Systems, Inc., USA) was used based on
the manufacturer’s instructions.
Immunohistochemistry (IHC) and miRNA locked nucleic
acid (LNA) in situ hybridization (ISH)
In situ hybridization (ISH) was performed to validate miR-
141 expression in a commercial ovarian cancer tissue array
(OVC1021) (5 normal/benign samples and 97 cases of
ovarian cancer) (Pantomics Inc., CA, USA) using the miR-
CURY LNA™ microRNA ISH Optimization Kit 5 (FFPE)
(Exiqon, Vedbaek, Denmark) as described in our previous
study [22]. First, the tissue assay was deparaffinized and in-
cubated for 40 min at 37 °C with 20 μg/ml proteinase K.
Then, the array was dehydrated followed by hybridization
with a miR-141 probe (5'-DIG/CCATCTTTACCAGA
CAGTGTTA/DIG-3', 1:500) overnight at 50 °C. Next, anti-
DIG reagent (sheep anti-DIG-AP, 1:400) was added, and
the slide was incubated for 60 min at room temperature.
Then, AP substrate was freshly prepared and applied to the
slide for a 2 h incubation at 30 °C in a humidifying cham-
ber, avoiding the dark. Finally, a nuclear counterstain was
applied, and the slides were mounted with mounting
medium (Eukitt).
For the immunohistochemistry analysis, xylene and al-
cohol at different percentages were utilized for slide
deparaffinization and rehydration. Slides were then
immersed in sodium citrate buffer (pH6) and boiled for
20 min. Inhibition of the endogenous peroxidase was
carried out by applying 0.3% hydrogen peroxidase
(H2O2). The slides were incubated with an anti-KLF12
polyclonal antibody (1:600) at 4 °C overnight after block-
ing with 10% normal rabbit serum for 45 min. A stand-
ard streptavidin-biotin-peroxidase complex method was
used for staining, followed by counterstaining with
Mayer’s hematoxylin. The stained slides were reviewed
by two independent investigators. The results were ana-
lyzed by light microscopy, and scores were given based
on the intensity and the percentage of the stained
tissues.
In vivo studies
For the intraperitoneal model, stable SKOV3 miR-141-
expressing clones, or A2780cp shSu knockdown clone
and the scrambled controls (2 × 106) were intraperitone-
ally injected into 5-week-old female BALB/cAnN nude
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mice (or N = 5 per group for SKOV3 miR-141 or
A2780cp shSu, respectively). All mice were sacrificed
after 2 to 4 weeks, and intraperitoneal tumor nodules
were extracted and weighed to compare relative tumor
burden.
Statistical analysis
Statistical analysis was performed using SPSS 14.0
(SPSS). A receiver operating characteristic (ROC) curve
was applied to determine the cut-off points for the ISH
and IHC data. Student’s t-test (for parametric data) and
the Mann–Whitney test (for non-parametric data) were
used. The results are expressed as the mean ± SD from
at least three independent experiments. The χ2 test or
Fisher’s exact test was used to analyze the association of
miR-141 and KLF12 expression and the clinicopathologi-
cal parameters. The Pearson correlation was used to
show the inverse relationship of miR-141 and KLF12.
P < 0.05 was regarded as statistically significant.
Results
miR-141 is frequently upregulated in ovarian cancer
The loss of anchorage dependence is the main conse-
quence of tumor cell escape from detachment-induced cell
death (anoikis). Using miRCURY™ LNA Array profiling
(1264 miRNAs) analysis of two types of ovarian cancer
cells (+/− in the ability to form colonies in soft agar assays),
we found 18 upregulated miRNAs in the cell lines that
could form colonies in soft agar (Fig. 1a). Among these 18
miRNAs, 12 potential candidates with higher than 2-fold
changes in the median log ratios were selected for further
functional screening. Soft agar assays were performed with
ovarian cancer cells ectopically expressing the selected pre-
miRNAs. The results showed that miR-141 significantly
increased the anchorage-independent growth of ovarian
cancer cells. However, other miR-200 family members,
such as miR-200b/200c/429 and miR-200a, also showed
high expression levels in ovarian cancer cells (Fig. 1a) but
had no obvious anchorage-independent effects (data not
shown), indicating that only miR-141 of the miR-200
family is involved with promoting anoikis resistance in
ovarian cancer cells. The miRNA microarray findings were
confirmed by comparing HOSE cell lines and ovarian can-
cer cell lines. Real-time quantitative RT-PCR (qPCR) was
employed to assess a panel of ovarian cancer cell lines
(SKOV3, ES2, OVTOKO, A2780S, OV429, OVISE,
OVCA433, RMG-1, A2780cp, OV420) and three immor-
talized HOSE cell lines (HOSE17-1, HOSE 96-9-10 and
HOSE 11–12). Our data showed that miR-141 was
frequently upregulated in the ovarian cancer cell lines
Fig. 1 Mir-141 is frequently upregulated in advanced ovarian cancers. a A graph showing 18 miRNAs with the highest expression in microRNA
profiling analysis which was performed using the miRCURY LNA™ miRNA array (Exiqon) on two types of ovarian cancer cell lines; anchorage-growth
independent (A2780s, A2780cp, SKOV3, C13*), and anchorage-growth dependent (HOSEs). The dot line shows the miRNAs with more than 2 folds of
Delta LogMedianRatios were selected for further functional analysis using transfection of their pre-miRNA expressing plasmids in ovarian cancer cell
lines e.g. A2780cp and SKOV3 and performing of soft agar assay. b Real time qPCR analysis showed that miR-141 is upregulated in ovarian cancer cell
lines (N = 12) as compared with the immortalized cell lines, HOSEs, (N = 3). Samples were normalized with SNORD48. c Graphical representation of qPCR
analysis showing that miR-141 is elevated in ovarian cancer (N = 65) when compare to the control normal ovary tissues (N = 26) and immortalized cell
lines (N = 3). d Representative pictures showing miR-141 ISH expression signal (dark blue staining) is gradually increased along the tumor stages of
epithelial ovarian cancer. (Magnification × 10; scale bar, 100 μm)
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(N = 12) and ovarian cancer clinical samples (N = 49)
compared to either normal ovarian tissues (N = 12) or
HOSE cells (N = 3) (Fig. 1b & c). Furthermore, con-
sistent with the findings in the cell lines, the mean
expression level of miR-141 in clinical ovarian cancer
samples (N = 49) was found to be ~10-fold higher
than that of normal ovary tissues (N = 12) as well as
the HOSE cell lines (Fig. 1c). In situ hybridization
was then performed on a commercial human ovarian
cancer tissue array (OVC1021, Pantomics), which fur-
ther confirmed that the upregulation of miR-141 in ad-
vanced ovarian cancer is significantly correlated with
cancer metastasis (Fig. 1d, Table 1). These findings suggest
that upregulation of miR-141 is common in ovarian can-
cers, especially late-stage ovarian cancer.
Increased miR-141 augments anchorage-independent
growth and survival of ovarian cancer cells in vitro and
tumor growth in vivo
Upregulated miR-141 was strongly associated with
advanced ovarian cancers, which is consistent with a
previous study [23]. To confirm the oncogenic functions
of miR-141, a miR-141 precursor-expressing plasmid
(pmR-ZsGreen1 vector, Clontech) was stably transfected
into three advanced ovarian cancer cell lines: A2780CP
(p53 mutated) (141-C2 and 141-C8), OVCA433 (p53
wildtype) (141-C5 and 141-C10) and SKOV3 (p53
deleted) (141-C1 and 141-C4) (Fig. 2a, left panel). An
ability to survive in the stressful microenvironment is
one of the pre-requisites for the development of anoikis
resistance in cancer cells. Therefore, we examined the
cell viability of stable miR-141-expressing clones under
low serum conditions (1% FBS). Using XTT cell prolifer-
ation assays, we showed that all miR-141-expressing
clones had significantly higher proliferation rates (3- to
4-fold) than the scrambled controls (Fig. 2b, left panel).
Furthermore, foci formation assays also confirmed that
stable miR-141-expressing clones of the three cell lines
exhibited increased cell viability (Fig. 2c, left panel)
under low serum (1%) culture conditions. The ability to
survive in unfavorable conditions provides advantages to
cancer cells in acquiring anoikis resistance. To evaluate
cancer cell resistance to anoikis, soft agar assays were
used. Stable miR-141-expressing clones of A2780cp
(141-C2 and 141-C8) and SKOV3 (141-C2 and 141-C3)
were tested in this assay. Our results revealed that the
clones A2780cp (141-C2 and 141-C8) exhibited a substan-
tial increase in size (~10-fold) and number (1.5- to 2-fold),
and the SKOV3 stable clones (141-C2 and 141-C3) also
exhibited an increase in size (~2- to 4-fold) and number
(1.5- to 2-fold) in soft agar compared with the vector con-
trols (Additional file 2: Figure S1).
Then, miR-141 was inhibited by the anti-miR™ miRNA
Inhibitor (Ambion) in the miR-141-enriched OVCA433
and SKOV3 cells (Fig. 1b). The depletion of miR-141 in
OVCA433 and SKOV3 (Fig. 2a, right panel) led to a sig-
nificant reduction in cell viability by 38 to 45% (Fig. 2b,
right panel) and the number of foci by 45 to 65% (Fig. 2c,
right panel) in the ovarian cancer cells cultured in low
serum medium. Taken together, these findings suggested
that miR-141 plays a crucial role in mediating cell sur-
vival under stress condition in ovarian cancer cells.
KLF12 is a direct target of miR-141 in ovarian cancer
One miRNA can modulate a wide range of downstream
targets; thus, we examined the potential downstream tar-
gets of miR-141 that may mediate these tumorigenic be-
haviors in ovarian cancer cells. Through an in silico
study using three bioinformatics algorithms (PicTar,
Miranda, and TargetScanHuman 6.0), we successfully
sorted out 65 potential genes from the above 3 programs
using gene ontology terms according to the Database for
Annotation, Visualization and Integrated Discovery
(DAVID) [24] (Fig. 3a). Ontology analysis using miRNA_
Targets database [25] identified that those potential targets
are involved in metabolic process, biological regulation,
localization and cellular process (Fig. 3b). Notably, some
potential genes have been previously reported that they
are the direct targets of miR-141 and are associated with
cell proliferation and metastasis of human cancers. For ex-
amples, PAPP-A, a factor of metabolic process, is fre-
quently found in invasive breast cancer [26, 27]; FUS, a
binding protein, is associated with neuroblastoma’s prolif-
eration, migration and survival [28]; DLC1 is a well-
known tumor suppressor for a variety of human cancers
[29]; as well as IRS2 is a suppressor of cell proliferation
and invasion of thyroid cancer [30]. Interestingly, there is
a potential target, SIK1, has previously reported to be
associated with anoikis resistance and metastasis via
interaction with LKB1 and in p53-dependent manner [31].
Table 1 Clinicopathological correlation of the expression of
miR-141 in an ovarian cancer tissue array (OVC1021). The 5-fold
cut-off was determined by ROC analysis
Parameters n(=97) miR-141 expression
≤5-fold >5-fold p
Grade
Low (1 + 2) 50 24 (48%) 26 (52%)
High (3) 46 24 (52%) 22 (48%) 0.838
Stage
Early (1) 48 31 (65%) 17 (35%)
Late (2 + 3) 49 18 (37%) 31 (63%) 0.008*
Metastasis
Yes 24 5 (21%) 19 (79%)
No 73 44 (62%) 29 (38%) 0.001*
*P < 0.05
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Likewise, our findings demonstrated that increased
miR-141 significantly enhances the anoikis resistance of
ovarian cancer cells. Among these cell lines, some cell
lines, such as A2780cp and SKOV3, harboring mutated or
deleted p53, suggesting that the increased anoikis resist-
ance of ovarian cancer cells does not solely depend on
SIK1/LKB1/p53 axis. To explore other putative targets as-
sociated with anoikis resistance in ovarian cancer cells, we
next analyzed other potential targets which are involved in
cell survival and have high score in algorithms prediction.
In line with two known targets of miR-141; SIK1 and FUS,
we also evaluated the expression of another three putative
targets; E2F3, MAP2K4 and KLF12 (Fig. 3c). Our western
blot analysis showed that overexpression of miR-141 and
transfection of anti-miR141 could remarkably reduce and
increase the expressions of SIK1 and KLF12, respectively
(Fig. 3d). However, FUS, MAP2K4 and E2F3 just showed
minor or even no change in the expressions (Fig. 3d). To
further confirm these three putative targets was controlled
by miR-141, the 3'UTR regions flanking the miR-141
binding sites of each target were subcloned into a
luciferase reporter vector, pmirGLO, generating pmirGLO-
MAP2K4, pmirGLO-E2F3 and pmirGLO-KLF12. Lucifer-
ase reporter assays of cells co-transfected with miR-141
and the three target plasmids revealed that the E2F3 and
MAP2K4 vectors only showed a 10% reduction in lucifer-
ase reporter activities (P < 0.005), while KLF12 showed a
35% reduction (P < 0.001) compared with the vector con-
trol (Additional file 3: Figure S2). This finding is in line
with the above western blot analysis (Fig. 3d), indicating
E2F3 and MAP2K4 may not the direct targets of miR-141.
On the other hand, further analysis indicated that miR-141
could significantly reduce the pmirGLO-KLF12 luciferase
activity in a dose-dependent manner (P < 0.035) (Fig. 3e).
Fig. 2 miR-141 enhances ovarian cancer cell survival. QPCR analyses showed the expressions of miR-141 in, (a) (left) miR-141-overexpressing
clones of A2780cp, OVCA433 and SKOV3; (right) and anti-miR141 treated cell lines; OVCA433 and SKOV3. VC: empty control and SC: scrambled
control. b (left) XTT cell proliferation demonstrated that overexpression of miR-141 could remarkably enhanced the cell proliferation in A2780cp,
OVCA433 and SKOV3 cell lines; (right) while inhibition of miR-141 significantly attenuated the cell proliferation in OVCA433 and SKOV3 cells with
treatment of anti-miR141. The foci formation assay demonstrated that, (c) (left) overexpression of miR-141 could increase the cell viability in
low-serum medium (0.1% FBS) compared with the vector control, (right) while depletion of miR-141 led to a reduction of cell viability
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There are 3 conserved (2 types of miR-141 target se-
quence) and 2 poorly conserved (one type of miR-141 tar-
get sequence) miR-141 binding sites in the KLF12 3'UTR
(Fig. 3f). Using luciferase reporter assays, we found that
miR-141 could significantly attenuate the luciferase activity
from the reporter fused to the C1 miR-141 target sequence
(GTCACAAT) of the KLF12 3'UTR by 51% and the C2
miR-141 target sequence (TCACAAT) by 14%, while there
was no effect on the pC1 poorly conserved miR-141 target
sequence (CAGTGTT) (Fig. 3g). Additionally, a point mu-
tation (AACCAAT) in the miR-141 seed region in the
3'UTR (pmiRGLO-KLF12-MUT) abolished the suppressive
effect on luciferase activity (Fig. 3g). To determine whether
there is an inverse correlation between miR-141 and
KLF12 expression, the ovarian cancer cell lines OVCA433,
A2780CP and SKOV3 were transiently transfected with
miR-141. The qPCR analysis confirmed the ectopic expres-
sion of miR-141 in the cell lines (1- to 30-fold), while a
simultaneous reduction in KLF12 expression of 20 to 60%
was observed (Fig. 3h). Moreover, western blotting also
confirmed that the expression levels of KLF12 and miR-
141 were inversely correlated in miR-141 overex-
pressed OVCA433 and A2780CP cells, and miR-141-
depleted SKOV3 and OVCA433 cells using anti-miR™
miRNA Inhibitor (Fig. 3i). These results suggest that miR-
141 regulates a network of genes or signaling inside the
mammalian cells, while KLF12 is a direct downstream tar-
get of miR-141, and miR-141 could inhibit the expression
of KLF12 mRNA and protein levels.
KLF12 exerts a tumor-suppressive effect on ovarian
cancer cells
As there is an inverse relationship between KLF12 and
miR-141, KLF12 may play an opposing role in ovarian
cancer cell tumorigenicity and may have relatively low
expression. Immunohistochemistry (IHC) was performed
Fig. 3 KLF12 is a direct target of miR-141. a The downstream targets of miR-141 were predicted by an in silico study using three bioinformatics
algorithms (PicTar, Miranda, and TargetScanHuman 6.0). b Ontology analysis using miRNA_Targets database 22 identified those predicted targets are
involved in metabolic process, biological regulation, localization and cellular process etc. c The putative miR-141 targets which may be associated with
anoikis resistance of ovarian cancer cells are categorized into six functional aspects. The red highlighted genes are the novel targets, while the black
color genes have been reported as the miR-141 direct targets. d Western blot analysis showed that enforced expression of miR-141 (+) could reduce,
while depletion of endogenous miR-141 by anti-miR-141 (+) could enhance the expressions of KLF12 and SIK1 only as compared with their controls
(−) in ovarian cancer cells. But the expressions of other putative downstream targets; FUS, E2F3 and MAP2K4 had little or no change when the level of
miR-141 was altered. e Luciferase reporter assay was performed in HEK293 cells and showed that the 3’ UTR of KLF12 luciferase activity was significantly
inhibited by miR-141 expression dependently. f A schematic diagram shows the putative binding sites for miR-141 on the whole 3'UTR region of
KLF12. Transient transfection of miR-141 mitigated the expression of KLF12 3’UTR-luciferase reporter activity. The KLF12 3’UTR with C1 binding site
showed the highest suppression by miR-141. g (Left panel) The schematic diagram shows the most conserved and common pairing of wild-type and
its mutant target regions of KLF12 and miR-141. (Right panel) The bar chart shows that miR-141 remarkably reduced the wild-type, whereas the
KLF12_3’UTR mutant showed no change in luciferase reporter activity. h QPCR showed that miR-141 could reduce the expression of KLF12 mRNA in
ovarian cancer cell lines. i Stable expression of miR-141 significantly reduced the expression of KLF12 in A2780cp and OVCA433 cells, while depletion
of miR-141 using anti-miR-141 restored the expression of KLF12 in SKOV3 cells
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on the same human ovarian cancer tissue array used for
the evaluation of miR-141 expression by ISH (OVC1021,
Pantomics). Together with the ISH findings, the IHC
results demonstrated that high expression of miR-141
was significantly associated with low expression of
KLF12 (N = 97, P < 0.001) (Fig. 4a) (Tables 1 and 2). Not-
ably, clinicopathological analysis showed that both high
expression of miR-141 (>5-fold) and low expression of
KLF12 (≦5-fold) were significantly correlated with late-
stage cancers (P = 0.008 for high expression of miR-141
and P = 0.000 for low expression of KLF12) and metastasis
(P = 0.001 for high expression of miR-141 and P = 0.01 for
low expression of KLF12) (Tables 1 and 2). Further study
by analyzing Pan-Cancer miRNA-mRNA interaction maps
from the Cancer Genome Atlas (TCGA) matched
miRNA-Seq and RNA-Seq data using StarBase V2.0
[32, 33] (http://starbase.sysu.edu.cn/index.php), we found
that the inverse correlation between miR-141 and KLF12
is not only observed in ovarian cancers but also other can-
cer types (11/14) (Additional file 1: Figure S3). This sug-
gests that this inverse relationship between miR-141 and
KLF12 is generally found in human cancers.
On the other hand, overexpression of KLF12 showed a
1- to 2-fold reduction in cell growth in the OVCA433 and
SKOV3 cells cultured in low serum media (Fig. 4b), a 2-fold
reduction in foci formation in OVCA433 cells (Fig. 3c), and
a 5- to 7-fold reduction in colony formation in soft agar
assays for OVCA433 and SKOV3 cells (Fig. 4d). In contrast,
stable knockdown of KLF12 in two highly expressing
KLF12 cell lines, A2780cp and OVCA433 (Fig. 4e), showed
a 0.2- to 2.5-fold increase in cell growth (Fig. 4f) and a 10%
to 30% increase in foci formation (Fig. 4g). These findings
demonstrate that KLF12 acts a downstream target of
miR-141 and a tumor suppressor in ovarian cancers.
Fig. 4 KLF12 expression inversely correlates with miR-141 and exerts inhibitory effects on ovarian cancer tumorigenicity. a Representative pictures
showing miR-141 expressions examined by ISH (dark blue staining) is inversely correlated with KLF12 expression detected by IHC (brown staining)
in early and advanced ovarian cancers. (Magnification × 10; scale bar, 100 μm). b Overexpression of KLF12 in two ovarian cancer cells; OVCA433
and SKOV3 (Upper), significantly suppresses their cell growth rates (Day 3 vs Day 1) examined by XTT cell proliferation assay when compared the
cell growth rate of their empty vector controls, VC. c Focus formation assay revealed that overexpression of KLF12 significantly inhibit the number
of foci in OVCA433 and SKOV3 cultured in low serum medium for 14 days. d The soft agar assay showed that overexpression of KLF12 remarkably
reduce the number and size of colonies formed in soft agar in OVCA433 and SKOV3 cells as compared with their empty vector controls. The
above assays represent the error bars with mean ± SD of at least 3 independent experiments. e Western blot analysis revealed that three KLF12 stable
clones were obtained from transfection of shRNAi of KLF12 in OVCA433. SC represents scrambled control. These results were obtained from at least
three experiments. f XTT cell proliferation assay showed that there was a significant increase of cell growth rate in all three KLF12 knockdown clones
as compared with the scramble control (SC). g The focus formation assay showed that there were two KLF12 knockdown clones (KD2 and KD4) had a
significant increase in the number of foci
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miR-141 confers anoikis resistance by suppressing KLF12
in ovarian cancer cells
Given that miR-141 is involved in promoting resistance to
the stress microenvironment in ovarian cancer cells, we
next investigated whether miR-141 increases anoikis re-
sistance in ovarian cancer cells. Anoikis is a type of apop-
tosis induced by inappropriate cell-matrix interactions
[34], and the anoikis assay is a method that mimics the
microenvironment of the cells when the extracellular
matrix attachment is absent [35] (Fig. 5a). Upon pre-
treatment with the anoikis method, OVCA433 cells over-
expressing miR-141 and with knockdown of KLF12
showed fewer apoptotic cells (red signals) (overexpressing
miR-141, 3-fold; knockdown of KLF12, 3- to 8-fold) com-
pared with their scrambled controls using TUNEL assays,
indicating that there is a substantial reduction in apoptosis
in OVCA433 cells (Fig. 5b). Flow cytometry analysis of
KLF12 knockdown clones or miR-141-overexpressing
clones further showed a reduction in the sub-G1 phase
(~28% reduction for KLF12 knockdown clones of
OVCA433 and ~56% for miR-141-overexpressing clones
of SKOV3) (Fig. 5c), indicating less apoptosis in KLF12
knockdown OVCA433 cells or miR-141-overexpressing
SKOV3 cells. Furthermore, western blotting revealed that
expressions of apoptosis-related factors, cleaved-PARP
and cleaved-caspase3, were reduced drastically (Fig. 5d).
Collectively, the above results indicate that the overex-
pression of miR-141 not only increases cell viability in
stress microenvironments but also confers anoikis resist-
ance to the ovarian cancer cells by inhibiting KLF12.
To examine the functional role of miR-141 in meta-
static peritoneal ovarian cancer growth and progression,
miR-141 was stably expressed in SKOV3 clones (N = 4),
and these cells and the vector controls (N = 4) were in-
traperitoneally (i.p.) injected into nude mice. After
4 weeks, tumor seeding and invasion were examined in
a post-mortem examination. Although injection of both
the vector control and the miR-141 clones resulted in
tumor nodule formation, tumor seeding was observed in
only three out of four mice in the vector control group
while all four mice in the miR-141 group showed a
greater extent of tumor burden. Moreover, compared
with the vector control, cells with stably expressing miR-
141 had a greater number of macroscopic tumor nodules
studding throughout the omentum and the peritoneal
cavity. Each mouse injected with the miR-141 clones
formed an average of more than 10 intraperitoneal
tumor nodules, while there was an average of approxi-
mately 2 nodules in the vector control group (Fig. 5e).
Taken together, these results further suggest that in
addition to promoting anoikis resistance, miR-141 also
promotes metastatic ovarian cancer cell growth and
tumor seeding in the peritoneal cavity, which is import-
ant in the metastatic process.
miR-141 serves as a novel modulator of the intrinsic
apoptotic pathway
To decipher the underlying molecular mechanism asso-
ciated with miR-141/KLF12-mediated anoikis resistance,
we examined their downstream targets. KLF12 is a tran-
scription factor that belongs to the Sp1/KLF family [36].
Affymetrix GeneChip 3' expression arrays were used
with mRNAs isolated from OVCA433 KLF12 stable
knockdown clones (KLF-KD4) to identify the down-
stream targets regulated by KLF12 (Fig. 6a). Using a fold
change >2 as a threshold, we identified a panel of differ-
entially expressed genes, particularly those related to the
apoptosis. Intriguingly, most highly altered genes re-
vealed by array profiling analysis were associated with
anti-apoptotic effects, e.g., CIAP2, Bcl2A1 and survivin
(Fig. 6a), supporting the hypothesis that KLF12 is crucial
in combating anoikis during cell detachment. Further-
more, using a Human Apoptosis Array Kit consisting of
35 apoptosis-related proteins (R&D) with either miR-141-
overexpressing or KLF12 knockdown ovarian cancer cells,
8 out of 35 proteins (HO-2/HMOX2, ph-Rad 17, CIAP-2,
survivin, HSP-70, TNFR1/TNFRSF1A, clusterin and
XIAP) were upregulated (Fig. 6b). Upregulation of
survivin was found in both GeneChip and the Human
Apoptosis Arrays (Fig. 6b). Survivin, a structurally unique
IAP protein, is a key regulator of the intrinsic apoptotic
pathway. Previous findings reported that survivin forms a
complex with XIAP and inhibits the activation of caspase-
3 and caspase-9, which in turn blocks the intrinsic
apoptotic pathway [37] and prevents cell apoptosis due to
anoikis stress. X-linked inhibitor of apoptosis protein
(XIAP), also known as inhibitor of apoptosis protein 3
Table 2 Clinicopathological and miR-141 correlation of the
expression of an ovarian cancer tissue array (OVC1021). The
5-fold cut-off was determined by ROC analysis
Parameters n(=97) KLF12 expression
≤5-fold >5-fold p
Grade
Low (1 + 2) 50 25 (50%) 25 (50%)
High (3) 46 24 (52%) 22 (48%) 0.841
Stage
Early (1) 48 14 (29%) 34 (71%)
Late (2 + 3) 49 36 (73%) 13 (27%) 0.000*
Metastasis
Yes 24 18 (75%) 6 (25%)
No 73 32 (44%) 41 (56%) 0.010*
miR-141
≤ 5 folds 50 14 (28%) 36 (72%)
> 5 folds 48 37 (77%) 11 (23%) 0.000*
*P < 0.05
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(IAP3), is also upregulated through association with the
increased survivin [38]. Hence, we speculated that the
miR-141-induced anoikis resistance is mediated through
suppression of KLF12, which, in turn, upregulates survivin
and XIAP expression to inhibit ovarian cancer cell apop-
tosis. Previous studies have suggested that the KLF family
shares homology with the transcriptional factor Sp1, and
therefore, they are grouped together in the Sp1/KLF
family [39]. Thus, we hypothesized that KLF12 and Sp1,
which share homology, may compete for binding sites on
the survivin promoter, hampering the transcriptional acti-
vation of survivin (Fig. 6c). To test this hypothesis, we first
used Sp1 motif from Jaspar database to search the Sp1-
binding elements (SEBs) on the survivin promoter
(Fig. 6d). Taking the promoter region (+/−1 k to TSS) of
survivin: chr17:76209278–76211277, we found that ten
putative SEBs (Additional file 4: Figure S4), showing
higher potential of Sp1 binding according to recent
findings [40]. By their affinity score and distribution on
survivin promoter, 7 out of 10 binding sites were
examined for the competition of SEBs occupancy between
Sp1 and KLF12 by ChIP assay (Additional file 4: Figure
S4). Results revealed that the occupancy of Sp1 on 3 out
of 7 SBEs of the survivin promoter were obviously inhib-
ited by KLF12 in A2780cp ovarian cancer cells (Fig. 6d),
supporting our notion of that KLF12 compete for the
binding sites of Sp1 on the survivin promoter and in turns
hampers the transcriptional activity of survivin.
To further prove that, we next examined whether the
transcriptional activity of survivin is upregulated by Sp1
using luciferase reporter assays. pCMV6-Sp1 and a sur-
vivin promoter luciferase plasmid (luc-survivin) (CH3
Biosystems) were co-transfected into HEK293 cells and
A2780cp cells. The results showed that the luciferase
activity of the survivin promoter was significantly in-
creased by ~3- to 5.5-fold in HEK293 cells and by ~48
to 70% in A2780cp cells by Sp1 in a dose-dependent
manner (Fig. 6e). In contrast, when luc-survivin and
pCMV6-Sp1 (600 ng) were co-transfected with varied
amounts of pCMV6-KLF12 (200–800 ng) in HEK293
Fig. 5 miR-141 promotes ovarian cancer cell growth and tumor seeding by enhancing anoikis resistance of ovarian cancer cells. a Experimental
overview of anoikis assay. b The relative apoptosis rates of miR-141 stable clones and KLF12 knockdown cells were measured using TUNEL assay.
Green signals represent DAPI positive cells and red signals represent TUNEL positive cells. Both overexpression of miR-141 or knockdown of KLF12
resulted in lower apoptotic rates of ovarian cancer cells after treated by anoikis assay. c Flow cytometry cell cycle analysis revealed that percentages
of sub-G1 phase in either KLF12 knockdown OVCA433 cells or miR-141 overexpressed SKOV3 cells were reduced as compared with their negative
controls. d Western blotting showed that either knockdown of KLF12 or overexpression of miR-141 could suppress ovarian cancer cell apoptosis
through reduction of cleaved-PARP and cleaved-caspase 3 expression in anoikis treated ovarian cancer cells (Upper: KLF12 knockdown clones in
OVCA433, Lower; miR-141 stable expressing clones in SKOV3). Bar, 50 μM. e Effects of miR-141 on ovarian cancer growth and tumor seeding were
revealed using in vivo model by i.p. injecting miR-141 and the scrambled control clones into 5-weeks old female nude mice. Average number of tumor
nodules (Left) and the tumor burden (Right) formed by miR-141 clones were much higher than the scrambled control and they were observed across
the peritoneal cavity as photographed on Day 28 (4 weeks). The white arrows indicate the location of tumor nodules
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and A2780cp cells, the luciferase reporter results showed
that the Sp1-upregulated survivin signals were strongly
reduced by KLF12 from 5-fold to 2-fold in HEK293 cells
and from 158% to 45% in A2780cp cells in a dose-
dependent manner (Fig. 6e). These results suggest that
KLF12 has an opposing function to Sp1 and augments
ovarian cancer cell survival by modulating the expres-
sion of survivin. To further verify these results, we tran-
siently transfected A2780cp and OVCA433 cells with
either Sp1 or KLF12. Western blot analyses indicated
that Sp1 could significantly elevate the expression levels
of survivin as well as XIAP, while KLF12 had the oppos-
ite effects compared to Sp1 and suppressed survivin and
XIAP expressions in both ovarian cancer cell lines
(Fig. 6f ). In contrast, stable knockdown of Sp1 in
OVCA433 and SKOV3 reduced the expression of survi-
vin and XIAP, while the expression of KLF12 was not
changed (Fig. 6g). These data suggest that the
overexpression of miR-141 or the loss of KLF12 en-
hances anoikis resistance in ovarian cancer cells by
modulating the Sp1/survivin/XIAP intrinsic apoptotic
pathway.
Survivin is required for enhancing anoikis resistance in
ovarian cancer cells
The above findings showed that the miR-141/KLF12/sur-
vivin signaling cascade is involved in the enhancement of
anoikis resistance in ovarian cancer cells. We questioned
whether survivin has a role in modulating anoikis resist-
ance in ovarian cancer cells, although mounting evidence
has indicated that survivin is frequently overexpressed in
human cancers [41] and involved in chemoresistance [42]
and metastatic progression [43]. We first knocked down
survivin using a shRNA approach in two ovarian cancer
cell lines, OVCA433 and SKOV3 (Fig. 7a). Foci formation
assays revealed that depletion of survivin reduced the
Fig. 6 Increased anoikis resistance in ovarian cancer cells is involved intrinsic apoptotic pathway. a The Affymetrix GeneChip 3' Expression Array
revealed a panel of apoptosis-related genes (Fold change >2) induced in KLF12 knockdown OVCA433 cells which showed increased anoikis resistance.
b Proteome Profiler (Human Apoptosis Array Kit) showed that 8 out of 35 Intrinsic Apoptosis-related factors were commonly upregulated in miR-141
enforced expression or KLF12 knockdown OVCA433 cells. c A schematic diagram illustrates that there are several Sp1 binding sites located along the
promoter of survivin, confirming Sp1 is able to transcriptionally upregulate survivin. KLF12 is able to interfere the interaction of Sp1 with the promoter
of survivin and the transcriptional activity. d ChIP assay showed the competitive occupancy of Sp1 by KLF12 on the promoter of survivin. (Upper)
Position weight matrix (PWM) for SP1-binding sequence motif derived from Jaspar database. ChIP assays showed the occupancy of Sp1 on 3 SBEs
(Red color) of the Survivin promoter in A2780cp cells were inhibited by KLF12. (Lower) Schematic diagram shows the positions of seven higher binding
affinity SBEs on the survivin promoter. e Luciferase reporter assay using Survivin promoter luciferase reporter construct (luc-Survivin) demonstrated
that Sp1 could significantly elevate the luciferase reporter signals from ~3-5.5 folds in HEK293 and ~48 to 70% in A2780cp by Sp1 dose dependently
(200 to 1000 ng/well) (Upper). Using luc-survivin and pCMV6-AC-GFP-Sp1 (600 ng/well) and co-transfected with varied amount of pCMV6-KLF12
(200–800 ng/well), results showed that the Sp1-upregulated survivin signals were remarkably reduced from 5 to 2 folds in HEK293, and from 158% to
45% in A2780cp by KLF12 in a dose-dependent manner (200 – 1000 ng/well). f Western blot analysis showed that transient transfection of Sp1 could
upregulate, while KLF12 could inhibit, survivin and XIAP expressions in A2780cp and OVCA433 cells. g Western blot analysis confirmed that knockdown
of Sp1 had no effect on KLF12 expression but significantly reduced the expression of survivin and XIAP in two Sp1-enriched ovarian cancer cell lines,
OVCA433 and SKOV3
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number of foci by 48% to 65% in these two cell lines
(Fig. 7b). In addition, the cell migratory capacity of survi-
vin knockdown SKOV3 and OVCA433 clones was re-
duced by 2.5- to 3-fold compared with their scrambled
controls (Fig. 7c). Moreover, upon treatment with the
anoikis assay, the depletion of survivin in these two cell
lines caused a substantial increase in the cell apoptotic
rate by 2- to 3-fold (Fig. 7d).
Finally, to examine the functional role of survivin in
metastatic potential of ovarian cancer cell growth and
progression in peritoneal cavity, survivin knockdown
was performed in another ovarian cancer cell line;
Fig. 7 Survivin is required for anoikis resistance, cell proliferation, cell migration and tumor colonization of ovarian cancer cells. a Western blot
analysis revealed that stable knockdown of survivin clones were established in OVCA433 and SKOV3 cells. b Focus formation assay demonstrated
that knockdown of survivin significantly reduce both number and size of focus. c Stable knockdown of survivin also significantly impaired the
cell migration capacity of ovarian cancer cell lines; SKOV3 and OVCA433 cells. d Upon anoikis assay treatment, results showed that depletion of
survivin by shRNAi remarkably increase the number of TUNEL positive signals (RED signals) as compared with their scrambled controls (SC),
indicating there is increased apoptotic rates of survivin-knockdown ovarian cancer cells. Bar, 100 μM. e Effects of survivin knockdown on ovarian
cancer colonization. Western blot analysis confirmed 80% survivin was knockdown by lentiviral shRNAi approach. Both ovarian cancer cells with
stably knockdown of survivin and scrambled control (SC) of A2780cp were i.p. injected into 5-weeks old female nude mice. Average number of
tumor nodules and the tumor burden formed by survivin knockdown clone were much lower than the scrambled control and the tumor nodules
stunning throughout the peritoneal cavity as photographed on Day 21 (3 weeks). The blue arrows point out the position of tumor nodules
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A2780cp has been shown to highly express survivin and
displays highly tumorigenicity in nude mice (Fig. 7e)
[44]. The stable A2780cp survivin knockdown cells (80%
knockdown) (Fig. 7e) (N = 5) and the vector control cells
(N = 5) were intraperitoneally (i.p.) injected into nude
mice, similar to the above in vivo tumorigenic assay, to
examine the functional role of miR-141 in ovarian can-
cer cells. After 2 weeks, tumor growth was investigated
by post-mortem examination. Compared with the
scrambled control (SC), the survivin knockdown clone
(shSu) resulted in fewer tumor nodules; tumor growth
was observed in only one out of five mice in the survivin
knockdown (shSu) group compared with four of five
mice in the scrambled control (SC) group (Fig. 7e).
Moreover, compared with the scrambled control group,
knockdown of survivin resulted in a substantial reduc-
tion in the number of macroscopic tumor nodules in the
omentum and the whole peritoneal cavity. The tumor
mass of the survivin knockdown clone was ~4-fold less
than that observed in the scrambled control (Fig. 7e).
Taken together, these results suggest that survivin is re-
quired for anoikis resistance and metastatic progression
of ovarian cancer cells in peritoneal metastases.
Discussion
The acquisition of anoikis resistance in cancer cells in
response to ECM detachment during cancer progression
is responsible for the difficulties in treatment and unsat-
isfactory clinical management for different types of can-
cers. Thus far, the underlying molecular mechanisms of
this process in cancer cells have received more attention
recently, and many important findings have been re-
ported [45, 46]. However, studies examining how ovarian
cancer cells escape anoikis during metastasis still remain
rare. In this study, we showed that the upregulation of
miR-141 and the subsequent suppression of KLF12 are
essential for anoikis resistance in ovarian cancer cells
both in vitro and in vivo. We also demonstrated that the
expression of survivin mRNA and protein increased
drastically when miR-141 was expressed ectopically or
Sp1 was overexpressed. The robust expression of survi-
vin and its downstream target, XIAP, serves as a bridge
between miR-141 and inhibition of intrinsic apoptotic
pathway. Knocking down KLF12 produced results simi-
lar to miR-141-induced anoikis resistance. But depletion
of survivin by shRNAi approach remarkably reduced
anoikis resistance of ovarian cancer cells and suppressed
their tumor colonization in peritoneal cavity of mice,
suggesting survivin is the major downstream effector of
miR-141/KLF12. Importantly, the inverse correlation
between miR-141 and KLF12 expression was clinically
confirmed of that the miR-141/KLF12/Sp1/survivin is a
new signaling axis required for anoikis resistance of
ovarian cancers during metastatic progression.
The dysregulation of miRNAs has been shown to be as-
sociated with cancer progression [47, 48]. The expression
of the miR-200 family, including miR-141, is usually
expressed differentially in various human cancers [49].
Previous studies have documented that the members of
this family are downregulated and could suppresses
epithelial-mesenchymal transition (EMT), while some
members of this family are upregulated and could pro-
mote mesenchymal-epithelial transition (MET) in cancer
development [50–52]. On the contrary, the miR-200 fam-
ily in advanced and high-grade ovarian and breast cancers
is frequently overexpressed and is closely related to distant
metastasis [53, 54]. Indeed, the overexpressed miR-141
has been reported in association with increased chemore-
sistance and cell survival of ovarian cancer cells under
oxidative stresses [55, 56]. In line with these studies, we
showed that miR-141 is significantly upregulated in
ovarian cancer cell lines and advanced metastatic ovarian
cancers. Importantly, the expression of miR-141 showed
an increased stepwise along the tumor stages, indicating
miR-141 plays a crucial role in promoting ovarian cancer
progression. Previous findings have shown that the
miR-200 family is well-known for their EMT-suppressive
and MET-promoting functions in other human cancers
[57, 58]. However, little is known about their tumor-
promoting abilities in metastatic ovarian cancers. In this
study, a convergence of functional assays demonstrated
that miR-141 not only elevates the viability of ovarian can-
cer cells in stressful microenvironments but also promotes
anchorage independence, resulting in increased anoikis re-
sistance in vitro and tumor growth and colonization in
vivo. Anoikis resistance is the initial event and must be ac-
quired by tumor cells when they undergo metastasis. In
successful metastasis, anoikis resistance is important for
cell survival in the circulation before the cells reach a dis-
tant location with a suitable ECM for reattachment to
form a new niche. It is known that one miRNA could
regulate a network of signaling through targeting a num-
ber of downstream targets [59]. In analysis across three
well known miRNA target prediction programs; PicTar,
miRanda and TargetScan 6.0, we found that there are 65
putative targets which can be further categorized into sev-
eral main biological functions such as metabolic process,
localization, cellular process, biological regulation, apop-
totic process and cell survival. Intriguingly, some of the
possible miR-141 targets are associated with cancer me-
tastasis e.g. DLC1 [29], insulin receptor substrate 2 (IRS2)
[30] and salt-inducible kinase 1 (SIK1) [31]. SIK1 is par-
ticularly of interest because SIK1 is able to interact with
LKB1 which in turn, enhances p53-dependent anoikis and
suppresses cancer metastasis [31]. However, our findings
in this study showed that the overexpressed miR-141
could enhance anoikis resistance not only in p53-wildtype
(OVCA433), but also in p53-mutated (A2780cp) and
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p53-deleted (SKOV3) ovarian cancer cell lines. That means
there are other signalings governing anoikis resistance in
ovarian cancers. Previous studies reported that some miR-
141 targets function in cell survival and biological process
could enhance chemoresistance and cell survival such as
FUS and PAPP-A [27, 28]. These findings urged us to look
into which possible targets in cell survival are involved in
anoikis resistance of ovarian cancers. As expected, in com-
bination of a series of functional and biochemical analyses,
KLF12 is a direct target of miR-141 and importantly, the
inverse relationship of KLF12 and miR-141 is significantly
correlated with the advanced and metastatic ovarian
cancers. KLF12 is a zinc finger protein that belongs to the
relatively large SP/KLF family of transcription factors. The
family consists of 25 members that regulate a wide range
of cell functions, including different aspects of cancer pro-
gression. Most KLFs are upregulated in the early stages of
cancer and are known to inhibit cancer cell invasiveness.
However, the expression of EMT-suppressing KLFs is
predominantly downregulated when the cells undergo sys-
temic dissemination, which usually occurs in the advanced
stages [60]. These findings support our clinicopathological
analysis of the inverse correlation between miR-141 and
KLF12 is related to cancer metastasis. Such inverse
relationship between miR-141 and KLF12 is also confirmed
in other human cancer types according to TCGA database.
Furthermore, a recent study reported that KLF12 is a novel
metastasis-suppressor gene and suppression of KLF12
resulted in anoikis resistance in lung cancer cells [61]. This
suggests that miR-141 protects ovarian cancer cells from
anoikis by suppressing KLF12 expression.
The study of anoikis is a new area in cancer research and
thus, increasing evidence has suggested that the initiation
and execution of anoikis is mediated by different pathways.
The interplay between the intrinsic and extrinsic apoptotic
pathways appears to be the most important. Although the
recent study demonstrated KLF12 enhances anoikis resist-
ance of lung metastatic cancer cells via regulating cell cycle
progression [61], our findings in this study showed another
mechanism of that the loss of KLF12 elevating the expres-
sion of survivin and its related intrinsic apoptotic pathway.
Overexpression of survivin, which belongs to the inhibitor
of apoptosis (IAP) proteins, may lead to cancer cell inva-
siveness, poor patient prognosis and low survival rates [62,
63]. The survivin anti-apoptotic network is mediated
through the survivin-XIAP complex, which subsequently
inhibits the activation of caspase-9 and the cleavage of cas-
pase3 and PARP. Apart from being an apoptotic regulator,
survivin also modulates cell cycle and proliferations [64].
Aberrant upregulation of survivin is frequently reported in
many human cancers and involves in tumor growth, me-
tastasis, chemoresistance and poor prognosis [64, 65]. In-
deed, our in vitro and in vivo tumorigenic studies
evidenced that survivin is required for anoikis resistance,
tumor growth and cancer cell colonization in peritoneal
metastases of ovarian cancer cells. This suggests that survi-
vin is a crucial modulator of the intrinsic pathway in
governing anoikis resistance of ovarian cancer cells.
Previous studies have suggested that the KLF family
shares homology with the transcription factor Sp1, and
therefore, they are grouped together as the Sp1/KLF family
[39]. There are eight Sp1 binding sites with canonical or
similar sequences [(G/T)(G/A)GGCG(G/T)(G/A)(G/A)(C/
T)] in the survivin promoter, and thus, Sp1 is a key tran-
scription factor for controlling the expression of survivin
[40]. Therefore, we hypothesized that KLF12 and Sp1,
which share homology, may compete for binding sites in
the survivin promoter, inhibiting the transcriptional activa-
tion of survivin. As expected, our ChIP assay demonstrated
that some Sp1 binding sites on survivin promoter are inter-
fered by KLF12. Consistently, luciferase reporter assays con-
firmed this model by showing a significant increase in the
luciferase signals under the control of the survivin promoter
when Sp1 was co-expressed, while a significant suppression
was observed when KLF12 was co-transfected with Sp1.
This finding was further verified by western blot analyses of
ovarian cancer cells transiently transfected with SP1 and
KLF12 or with a stable Sp1 knockdown. Taken together, our
study revealed that the overexpression of miR-141 augments
anoikis resistance in ovarian cancer cells by targeting and
repressing the expression of KLF12, which, in turn, com-
petes for binding sites in the survivin promoter with Sp1.
The subsequent increase in survivin then protects ovarian
cancer cells against anoikis by blocking the intrinsic apop-
totic activity.
Conclusions
This study highlights a novel signaling cascade of miR-
141/KLF12/Sp1/survivin in promoting anoikis resistance
of ovarian metastatic cancer cells and suggests a unique
molecular mechanism by which the intrinsic apoptotic
pathway is impeded in ovarian cancer tumors by
microRNA-mediated epigenetic regulation during ovarian
cancer metastatic progression (Additional file 5: Figure S5).
Conceivably, targeting this signaling axis could form the
basis for a novel therapeutic strategy to treat or even pre-
vent ovarian cancer micrometastases.
Additional files
Additional file 1: Figure S3. (Upper) By using StarBase V2.0
(http://starbase.sysu.edu.cn/index.php) as analytic tool to analyze the
inverse relationship between miR-141 and KLF12 in human cancers
according Pan-Cancer miRNA-mRNA interaction maps from the Cancer
Genome Atlas (TCGA) matched miRNA-Seq and RNA-Seq data, 11 out of
14 human cancer types showed the significant correlation. (Lower)
The scatter chart showed the inverse correlation of miR-141 and KLF12 in
265 cases of ovarian serous cancers (Pearson correlation r = −0.15369,
P value = 0.0122457). (TIF 327 kb)
Mak et al. Molecular Cancer  (2017) 16:11 Page 15 of 17
Additional file 2: Figure S1. Enforced expression of miR141 increases
anchorage-independent growth capacity of ovarian cancer cells. Soft agar
assay showed that stably expression of miR141 in A2780cp (141-C2 and
141-C8) and SKOV3 (141-C2 and 141-C3) could significantly increase the
number and size of the colonies as compared with their vector control
(VC). The pictures showed the representative colony morphology and size
of miR141 stable clones and vector control (VC). (TIF 311 kb)
Additional file 3: Figure S2. Putative targets for miR-141. Schematic
presentation of the miR-141 seed matches in the human KLF12, E2F3 and
MAP2K4 3'UTR introduced into the pmiRGLO luciferase 3'UTR constructs.
Luciferase reporter assay to assess the interaction of miR-141 with the
three putative target candidates, E2F3, MAP2K4 and KLF12 with the use
of HEK293 cells. Co-transfection of miR-141 and KLF12 luciferase plasmids
resulted in the strongest reduction of the luciferase reporter signals.
(TIF 3533 kb)
Additional file 4: Figure S4. (Upper) Taking the promoter region
(+/−1 k to TSS) of survivin: chr17:76209278–76211277, ten putative SEBs
higher potential of Sp1 binding ability were shown. (Lower) The genomic
sequences of primers targeting SBEs of Sp1 on the survivin promoter.
(TIF 681 kb)
Additional file 5: Figure S5. A schematic diagram summaries the
findings in this study. The overexpression of miR141 directly targets
KLF12 expression. The reduced KLF12 expression allows Sp1 interacting
with Survivin promoter that in turns, enhance the expression of survivin
in both mRNA and protein levels. Through the stabilization of XIAP, the
Survivin-XIAP complex which subsequently inhibiting the activation of
caspase-9 and the cleavage of caspase-3 and PARP in the intrinsic
apoptotic pathway and enhance anoikis resistance of advanced metastatic
ovarian cancer cells in the ascetic tumor microenvironment. (TIF 320 kb)
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